Agile Therapeutics Presents Additional Data At ACOG Meeting On Lead Contraceptive Patch Now Entering Phase 3
May 7, 2009 by admin
Agile Therapeutics, Inc., presented new detailed data on ethinyl estradiol (EE) and levonorgestel (LNG) hormone levels, safety and ovulation suppression on its lead product, AG200-15, an innovative low-dose weekly contraceptive patch now entering Phase 3 clinical trials to show efficacy, safety and tolerability.
Comments
Feel free to leave a comment...
and oh, if you want a pic to show with your comment, go get a gravatar!